cyclophosphamide + mitomycin c

Cyclophosphamide + mitomycin c is a combination chemotherapy regimen consisting of two antineoplastic agents—cyclophosphamide, an alkylating agent of the nitrogen mustard type, and mitomycin c, an antitumor antibiotic with alkylating properties. Both drugs act primarily by cross-linking DNA strands and inhibiting DNA synthesis, leading to cell death. This combination has demonstrated synergistic effects in preclinical models (notably murine leukemia), resulting in improved survival compared to either agent alone without increased toxicity[1][4][7]. Clinically, this combination has been used as part of multi-agent regimens for various cancers including ovarian cancer and advanced non-small cell lung cancer[2][3][8]. The rationale for combining these agents is their complementary mechanisms of action and non-overlapping toxicity profiles.

Other names

cyclophosphamide and mitomycin cCYC + MMCCYC/MMC